Softening the Rule of Five - Where to draw the line?

Joachim Petit, Nathalie Meurice, Christine Kaiser, Gerald Maggiora

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

In order to improve the discovery and development of new drugs, a broad effort is being made to assess the 'drug-like' properties of molecules in early stages of the discovery-research process. Although there are numerous approaches to this problem, perhaps the simplest and most widespread one is that developed by Chris Lipinski and his co-workers at Pfizer, which is generally referred either as the Lipinski Rules or the Rule of Five (ROF). The ROF is based on four properties of molecules, namely, molecular weight (MW), log P, number of hydrogen bond donors (HBD), and the number of hydrogen bond acceptors (HBA). A 'flag' is set if the value of a given property exceeds the chosen threshold value for that property - MW 500 Da, log P 5, the number of HBDs 5, and the number of HBAs 10. Each flag corresponds to an ROF violation. The total number of violations is the ROF-Score, which lies between '0' and '4'. Molecules with ROF-Scores greater than one are considered to be marginal for further development. The difficulty with this approach is that two molecules with nearly identical property values can, nonetheless, possess ROF-Scores that can differ by two or more. Thus, one molecule could be considered for further studies while the other, nearly identical molecule (in terms of its four ROF properties), would most likely not be. This problem arises because of the sharp thresholds imposed by the present formulation of the ROF, which is based upon classical sets. In the current work an alternative approach based on the use of utility functions, within the framework of the analytic hierarchy process (AHP), are employed to 'soften' the sharp boundaries inherent in classical sets. This provides a more realistic assessment of compounds in terms of their potential suitability in drug-discovery research programs.

Original languageEnglish (US)
Pages (from-to)5343-5351
Number of pages9
JournalBioorganic and Medicinal Chemistry
Volume20
Issue number18
DOIs
StatePublished - Sep 15 2012
Externally publishedYes

Fingerprint

Hydrogen
Molecular Weight
Molecules
Drug Discovery
Research
Pharmaceutical Preparations
Hydrogen bonds
Molecular weight
Analytic hierarchy process

Keywords

  • Analytic hierarchy process
  • Decision theory
  • Drug likeness
  • Lipinski Rules
  • Molecular properties
  • Soft Rule of Five
  • Utility functions

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Softening the Rule of Five - Where to draw the line? / Petit, Joachim; Meurice, Nathalie; Kaiser, Christine; Maggiora, Gerald.

In: Bioorganic and Medicinal Chemistry, Vol. 20, No. 18, 15.09.2012, p. 5343-5351.

Research output: Contribution to journalArticle

Petit, J, Meurice, N, Kaiser, C & Maggiora, G 2012, 'Softening the Rule of Five - Where to draw the line?', Bioorganic and Medicinal Chemistry, vol. 20, no. 18, pp. 5343-5351. https://doi.org/10.1016/j.bmc.2011.11.064
Petit, Joachim ; Meurice, Nathalie ; Kaiser, Christine ; Maggiora, Gerald. / Softening the Rule of Five - Where to draw the line?. In: Bioorganic and Medicinal Chemistry. 2012 ; Vol. 20, No. 18. pp. 5343-5351.
@article{a659e723599a49f9866aba276ed78684,
title = "Softening the Rule of Five - Where to draw the line?",
abstract = "In order to improve the discovery and development of new drugs, a broad effort is being made to assess the 'drug-like' properties of molecules in early stages of the discovery-research process. Although there are numerous approaches to this problem, perhaps the simplest and most widespread one is that developed by Chris Lipinski and his co-workers at Pfizer, which is generally referred either as the Lipinski Rules or the Rule of Five (ROF). The ROF is based on four properties of molecules, namely, molecular weight (MW), log P, number of hydrogen bond donors (HBD), and the number of hydrogen bond acceptors (HBA). A 'flag' is set if the value of a given property exceeds the chosen threshold value for that property - MW 500 Da, log P 5, the number of HBDs 5, and the number of HBAs 10. Each flag corresponds to an ROF violation. The total number of violations is the ROF-Score, which lies between '0' and '4'. Molecules with ROF-Scores greater than one are considered to be marginal for further development. The difficulty with this approach is that two molecules with nearly identical property values can, nonetheless, possess ROF-Scores that can differ by two or more. Thus, one molecule could be considered for further studies while the other, nearly identical molecule (in terms of its four ROF properties), would most likely not be. This problem arises because of the sharp thresholds imposed by the present formulation of the ROF, which is based upon classical sets. In the current work an alternative approach based on the use of utility functions, within the framework of the analytic hierarchy process (AHP), are employed to 'soften' the sharp boundaries inherent in classical sets. This provides a more realistic assessment of compounds in terms of their potential suitability in drug-discovery research programs.",
keywords = "Analytic hierarchy process, Decision theory, Drug likeness, Lipinski Rules, Molecular properties, Soft Rule of Five, Utility functions",
author = "Joachim Petit and Nathalie Meurice and Christine Kaiser and Gerald Maggiora",
year = "2012",
month = "9",
day = "15",
doi = "10.1016/j.bmc.2011.11.064",
language = "English (US)",
volume = "20",
pages = "5343--5351",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "18",

}

TY - JOUR

T1 - Softening the Rule of Five - Where to draw the line?

AU - Petit, Joachim

AU - Meurice, Nathalie

AU - Kaiser, Christine

AU - Maggiora, Gerald

PY - 2012/9/15

Y1 - 2012/9/15

N2 - In order to improve the discovery and development of new drugs, a broad effort is being made to assess the 'drug-like' properties of molecules in early stages of the discovery-research process. Although there are numerous approaches to this problem, perhaps the simplest and most widespread one is that developed by Chris Lipinski and his co-workers at Pfizer, which is generally referred either as the Lipinski Rules or the Rule of Five (ROF). The ROF is based on four properties of molecules, namely, molecular weight (MW), log P, number of hydrogen bond donors (HBD), and the number of hydrogen bond acceptors (HBA). A 'flag' is set if the value of a given property exceeds the chosen threshold value for that property - MW 500 Da, log P 5, the number of HBDs 5, and the number of HBAs 10. Each flag corresponds to an ROF violation. The total number of violations is the ROF-Score, which lies between '0' and '4'. Molecules with ROF-Scores greater than one are considered to be marginal for further development. The difficulty with this approach is that two molecules with nearly identical property values can, nonetheless, possess ROF-Scores that can differ by two or more. Thus, one molecule could be considered for further studies while the other, nearly identical molecule (in terms of its four ROF properties), would most likely not be. This problem arises because of the sharp thresholds imposed by the present formulation of the ROF, which is based upon classical sets. In the current work an alternative approach based on the use of utility functions, within the framework of the analytic hierarchy process (AHP), are employed to 'soften' the sharp boundaries inherent in classical sets. This provides a more realistic assessment of compounds in terms of their potential suitability in drug-discovery research programs.

AB - In order to improve the discovery and development of new drugs, a broad effort is being made to assess the 'drug-like' properties of molecules in early stages of the discovery-research process. Although there are numerous approaches to this problem, perhaps the simplest and most widespread one is that developed by Chris Lipinski and his co-workers at Pfizer, which is generally referred either as the Lipinski Rules or the Rule of Five (ROF). The ROF is based on four properties of molecules, namely, molecular weight (MW), log P, number of hydrogen bond donors (HBD), and the number of hydrogen bond acceptors (HBA). A 'flag' is set if the value of a given property exceeds the chosen threshold value for that property - MW 500 Da, log P 5, the number of HBDs 5, and the number of HBAs 10. Each flag corresponds to an ROF violation. The total number of violations is the ROF-Score, which lies between '0' and '4'. Molecules with ROF-Scores greater than one are considered to be marginal for further development. The difficulty with this approach is that two molecules with nearly identical property values can, nonetheless, possess ROF-Scores that can differ by two or more. Thus, one molecule could be considered for further studies while the other, nearly identical molecule (in terms of its four ROF properties), would most likely not be. This problem arises because of the sharp thresholds imposed by the present formulation of the ROF, which is based upon classical sets. In the current work an alternative approach based on the use of utility functions, within the framework of the analytic hierarchy process (AHP), are employed to 'soften' the sharp boundaries inherent in classical sets. This provides a more realistic assessment of compounds in terms of their potential suitability in drug-discovery research programs.

KW - Analytic hierarchy process

KW - Decision theory

KW - Drug likeness

KW - Lipinski Rules

KW - Molecular properties

KW - Soft Rule of Five

KW - Utility functions

UR - http://www.scopus.com/inward/record.url?scp=84866244593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866244593&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2011.11.064

DO - 10.1016/j.bmc.2011.11.064

M3 - Article

C2 - 22222160

AN - SCOPUS:84866244593

VL - 20

SP - 5343

EP - 5351

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 18

ER -